Trial · NCT01556906
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | LDL-C | Up to 16 weeks of treatment comapred to Baseline | All patients treated | percentage change in LDL-C | MEAN |
| SECONDARY | Absolute Change From Baseline in Alanine Aminotransferase (ALT) | Baseline and 16 weeks of treatment | All patients treated | U/L | MEAN |
| SECONDARY | Absolute Change From Baseline in Aspartate Aminotransferase (AST) | Baseline and 16 weeks of treatment | All patients treated | U/L | MEAN |
| SECONDARY | Absolute Change From Baseline in Total Bilirubin | Baseline and 16 weeks of treatment | All patients treated | mg/dL | MEAN |
| SECONDARY | Absolute Change From Baseline in Hepatic Fat Percent | Baseline and 16 weeks of treatment | All patients treated | percent of hapatic fat | MEAN |
| SECONDARY | Absolute Change From Baseline in Forced Expiratory Volume During 1 Second (FEV1) | Baseline and 16 weeks of treatment | All patients treated | Liters | MEAN |
| SECONDARY | Absolute Change From Baseline in Carbon Monoxide Lung Diffusing Capacity (DLCO)(a Pulmonary Function Test) | Baseline and 16 weeks of treatment | All patients treated | mL CO/min/mm Hg | MEAN |
| SECONDARY | Absolute Change From Baseline in Vitamin A | Baseline and 16 weeks of treatment | All patients treated | µmol/L | MEAN |
| SECONDARY | Absolute Change From Baseline in Vitamin E | Baseline and 16 weeks of treatment | All patients treated | umol/L | MEAN |
| SECONDARY | Absolute Change From Baseline in Vitamin D | Baseline and 16 weeks of treatment | All patients treated | nmol/L | MEAN |
| SECONDARY | Absolute Change From Baseline in Ratio of Vitamin E to Total Lipids | Baseline and 16 weeks of treatment | All patients treated | ratio | MEAN |
| SECONDARY | Absolute Change From Baseline in Alpha Linoleic Acid (ALA) | Baseline and 16 weeks of treatment | All patients treated | mg/mL | MEAN |
| SECONDARY | Absolute Change From Baseline in Eicosapentaenoic Acid (EPA) | Baseline and 16 weeks of treatment | All patients treated | mg/mL | MEAN |
| SECONDARY | Absolute Change From Baseline in Docosahexaenoic Acid (DHA) | Baseline and 16 weeks of treatment | All patients treated | mg/mL | MEAN |
| SECONDARY | Absolute Change From Baseline in Linoleic Acid (LA) | Baseline and 16 weeks of treatment | All patients treated | mg/mL | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01556906/outcomes